Literature DB >> 12165558

Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor.

Andrew P Lieberman1, George Harmison, Andrew D Strand, James M Olson, Kenneth H Fischbeck.   

Abstract

Kennedy's disease is a degenerative disease of motor neurons in which the causative mutation is expansion of a CAG/polyglutamine tract near the 5' end of the androgen receptor gene. The mutant protein misfolds, aggregates, and interacts abnormally with other proteins, leading to a novel, toxic gain of function and an alteration of normal function. We used a cell culture model to explore the mechanisms underlying the alterations in androgen receptor function conferred by the mutation. Here we show that cells expressing the wild-type androgen receptor with 24 CAG repeats respond to ligand by showing trophic effects including prolonged survival in low serum, whereas cells expressing the mutant receptor with 65 CAG repeats do not show a robust trophic response. This partial loss of function correlates with decreased levels of the mutant protein due to its preferential degradation by the ubiquitin-proteasome pathway. Expression analysis using oligonucleotide arrays confirms that the mutant receptor has undergone a partial loss of function, and fails to regulate a subset of genes whose expression is normally affected by ligand activation of the wild-type receptor. The mutant receptor has also undergone several functionally important post-translational modifications in the absence of ligand that the wild-type receptor undergoes in the presence of ligand, including acetylation and phosphorylation. These modifications correlate with a ligand-independent gain of function exhibited by the mutant receptor in expression analysis. Our findings suggest that polyglutamine expansion alters androgen receptor function by promoting its degradation and by modifying its activity as a transcription factor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165558     DOI: 10.1093/hmg/11.17.1967

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  61 in total

Review 1.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

2.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

3.  PolyQ disease: too many Qs, too much function?

Authors:  Ian H Kratter; Steven Finkbeiner
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

Review 4.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 5.  Spinal and bulbar muscular atrophy: pathogenesis and clinical management.

Authors:  C Grunseich; C Rinaldi; K H Fischbeck
Journal:  Oral Dis       Date:  2013-05-09       Impact factor: 3.511

Review 6.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

7.  Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery.

Authors:  Mariàngels de Planell-Saguer; David G Schroeder; Maria Celina Rodicio; Gregory A Cox; Zissimos Mourelatos
Journal:  Hum Mol Genet       Date:  2009-03-19       Impact factor: 6.150

8.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

9.  Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy.

Authors:  Kaiguo Mo; Zak Razak; Pengcheng Rao; Zhigang Yu; Hiroaki Adachi; Masahisa Katsuno; Gen Sobue; Andrew P Lieberman; J Timothy Westwood; D Ashley Monks
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

10.  Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Heather L Montie; Maria S Cho; Latia Holder; Yuhong Liu; Andrey S Tsvetkov; Steven Finkbeiner; Diane E Merry
Journal:  Hum Mol Genet       Date:  2009-03-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.